CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors

Official title

Chimeric Antigen Receptor T Lymphocytes (CAR-T) Targeting CEA in the Treatment of CEA Positive Clinical Study of Advanced Malignant Solid Tumors

Overview

This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CAR-T cell preparations, and to preliminarily observe the study drug in CEA-positive advanced malignant tumors. The pharmacokinetic characteristics of CAR-T cell preparations for the treatment of patients with CEA-positive advanced malignancies were obtained and the recommended dose and infusion schedule.

Detailed description

According to the different infusion methods, it is divided into two subgroups: intravenous infusion and local infusion through the peritoneal cavity. Each subgroup includes a dose exploration stage (Part A) and a dose expansion stage (Part B). 3 patients were explored, starting from the low-dose group, and in the dose expansion phase, the safety and efficacy were further verified according to the safe recommended dose obtained in the dose exploration phase.

Interventions

• Biological CEA-targeted CAR-T cells
  Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
• Biological CEA-targeted CAR-T cells
  Administration method: intraperitoneal injection；Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.

Primary outcome measures

• To evaluate the safety of CAR-T cell preparations in the treatment of CEA-positive advanced malignancies [Safety and Tolerability] [Time frame: 1 month]
• Obtained the recommended dose and infusion regimen of CAR-T cells for the treatment of patients with CEA-positive advanced malignancies[Safety and Tolerability] [Time frame: 28 days]

Secondary outcome measures (5)

• Assessing disease control rates of CAR-T cell preparations in CEA-positive advanced malignancies[Effectiveness] [Time frame: 3 months]
• AUCS of CEA CAR-T cells [Cell dynamics] [Time frame: 3 months]
• CMAX of CEA CAR-T cells [Cell dynamics] [Time frame: 3 months]
• TMAX of CEA CAR-T cells[Cell dynamics] [Time frame: 3 months]
• Pharmacodynamics of CEA CAR-T cells[Cell dynamics] [Time frame: 3 months]

Eligibility criteria

Inclusion criteria

• Age ≥18 years old, male or female;
• Advanced, metastatic or recurrent malignant tumors diagnosed by histology or pathology, mainly colorectal cancer, esophageal cancer, gastric cancer, and pancreatic cancer;
• After receiving at least second-line standard treatment failure (disease progression or intolerance, such as surgery, chemotherapy, radiotherapy, etc.) or lack of effective treatment methods;
• Immunohistochemical staining of tumor samples within 3 months confirmed that the tumor was CEA positive (clear membrane staining, positive rate ≥ 10%); , the positive rate ≥ 10%), the serum CEA of the patient is required to exceed 10ug/L.
• At least one assessable lesion according to RECIST 1.1 criteria;
• ECOG score 0-2 points;
• No serious mental disorder;
• Unless otherwise specified, the function of the vital organs of the subject shall meet the following conditions:

• Blood routine: white blood cells>3.0×10\^9/L, neutrophils>0.8×10\^9/L, lymphocytes cells>0.5×10\^9/L, platelets>75×10\^9/L, hemoglobin>80g/L;
• Cardiac function: echocardiography showed cardiac ejection fraction ≥50%, and no obvious abnormality was found on electrocardiogram;
• Renal function: serum creatinine≤2.0×ULN;
• Liver function: ALT and AST ≤3.0×ULN (for patients with liver tumor infiltration, it can be relaxed to ≤5.0×ULN);
• Total bilirubin≤3.0×ULN;
• Oxygen saturation ≥95% in non-oxygen state.
• Have apheresis or venous blood collection standards, and have no other contraindications for cell collection;
• Subjects agree to use reliable and effective contraceptive methods for contraception within 1 year after signing the informed consent form to receiving CAR-T cell infusion (excluding rhythm contraception);
• The patients themselves or their guardians agree to participate in this clinical trial and sign the ICF, indicating that they understand the purpose and procedures of this clinical trial and are willing to participate in the research.

Exclusion criteria

• Those who have central nervous system metastasis or meningeal metastasis at the time of screening are judged by the investigator to be unsuitable for inclusion;
• Participated in other clinical studies within 1 month before screening;
• vaccinated with live attenuated vaccine within 4 weeks before screening;
• Received the following anti-tumor treatments before screening: Received chemotherapy, targeted therapy or other experimental drug treatments within 14 days or at least 5 half-lives (whichever is shorter);
• Active infection or uncontrollable infection requiring systemic treatment;
• Patients with intestinal obstruction, active gastrointestinal bleeding, or a history of gastrointestinal bleeding within 3 months;
• Except for alopecia or peripheral neuropathy, the toxicity of previous anti-tumor therapy has not improved to the baseline level or ≤ grade 1;
• Suffering from any of the following heart diseases:

• New York Heart Association (NYHA) stage III or IV congestive heart failure;
• Myocardial infarction or coronary artery bypass grafting (CABG) within 6 months before enrollment;
• Clinically significant ventricular arrhythmia, or a history of unexplained syncope (except those caused by vasovagal or dehydration);
• History of severe non-ischemic cardiomyopathy;
• Patients with active autoimmune disease, or other patients requiring long-term immunosuppressive therapy;
• Suffering from other uncured malignant tumors in the past 3 years or at the same time, except cervical carcinoma in situ and basal cell carcinoma of the skin;
• Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA titer test is greater than the normal range; hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C Virus (HCV) RNA test is greater than the normal range; human immunodeficiency virus (HIV) antibody positive; syphilis test positive;
• Women who are pregnant or breastfeeding;
• Other investigators deem it unsuitable to participate in the research.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Non-randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Treatment

Study locations

China · 3 centers

• Shanxi Bethune Hospital — Taiyuan
• Shanxi Bethune Hospital — Taiyuan
• Shanxi Bethune Hospital — Taiyuan

Identifiers

NCT: NCT06006390 · PBC058

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗